Shares of antibiotic developer Tetraphase Pharmaceuticals (TTPH) are higher on Monday after a report out of Contagion Live this past Friday. According to the Contagion Live report, Tetraphase Pharmaceutical’s Chief Medical Officer shared Ignite4 phase 3 trial results which indicated that eravacycline proved to be non-inferior to meropenem for the treatment of complicated intra-abdominal infections or cIAI. Tetraphase describes itself ass a clinical-stage life science company with a synthetic chemistry technology platform that has the potential to address the global health crisis caused by antibiotic resistance.The drug company went public in 2013 and its stock rose as high as $53 per share in the summer of 2015 on the hopes of its lead drug, eravacycline. PAST DISAPPOINTMENT:Shares of Tetraphase dropped precipitously in the fall of 2015 when the company said that in Ignite2, its phase-three clinical trial against complicated urinary tract infections, eravacycline did not compare well with standard treatment levofloxacin, known as Johnson & Johnson’s (JNJ) Levaquin. RECENT RESULTS: According to Friday’s Contagion Live report, Tetraphase’s Ignite 4 phase 3 trial study “successfully met its primary efficacy endpoint, which was to demonstrate non-inferiority of eravacycline to meropenem for the treatment of cIAI. Furthermore, the antibiotic was found to be well-tolerated. These data support the use of eravacycline for the treatment of cIAI, including infections caused by pathogens resistant to other antibiotics, the authors concluded. PRICE ACTION: Shares of Tetraphase Pharmaceuticals are up almost 15% to $3.71 in afternoon trading.